‘Global Companion Diagnostics Market Will be Worth $3.45bn by 2015′ Predicts a Visiongain Report

LONDON, September 7, 2011 -

www.visiongain.com/Report/675/Companion-Diagnostics-World-Market-Outlook-2011-2021

A new report by visiongain, a London-based business information provider, predicts that the global companion diagnostics market will be worth $3.45bn by 2015. The market generated sales of $1.30bn in 2010, according to Companion Diagnostics: World Market Outlook 2011-2021, published in August 2011.

Companion diagnostics are diagnostic tests that are linked to a particular drug/therapy. This is a small, emerging market at present, but one of the fastest growing segments in the IVD market. The concept of a drug-diagnostic combination is not new, but has only started to garner interest, with the move of healthcare towards personalised medicine. Companion diagnostics combined with targeted therapeutics are the tools for providing personalised treatment. This market has significant potential for growth with the increasing demand for safer, efficacious drugs.

Rupali Vadhera, healthcare industry analyst, says: “The market for companion diagnostics has enjoyed strong growth in recent years, driven by adoption of marketed products, and also due to the increase in the number of theranostics. Theranostics are companion diagnostic tests, the use of which is essential before the corresponding drug is prescribed. Over the course of the next decade, there will be greater demand for the companion diagnostics, as they improve the safety-efficacy profile of drugs and help to reduce the healthcare costs.”

Visiongain’s research suggests that the world companion diagnostics market will benefit from developments in biomarker discovery and use in early stages of drug development. These biomarkers for disease can be developed into companion diagnostics for clinical use. Also benefiting the companion diagnostics market will be efforts on the part of the regulatory authorities to develop clearer regulatory guidelines for the co-development of companion diagnostics.

Visiongain predicts that this market will grow steadily to 2021. The future of the companion diagnostics market appears promising, with increases in the demand for high priced specialist therapies and the demand for safer, more-efficacious drugs. This new study adds to visiongain’s wide range of analytical reports in healthcare and other industry areas.

To view sample pages of the report please click on:

www.visiongain.com/Report/675/Companion-Diagnostics-World-Market-Outlook-2011-2021

Table of Contents
1. Executive Summary
1.1 Companion Diagnostics Market Review
1.2 Aims, Scope and Format of the Report
1.2.1 Chapter Outlines
1.3 Research and Analysis Methods

2. Introduction to Companion Diagnostics
2.1 Changing Paradigms of Treatment
2.2 What is Personalised Medicine?
2.3 In Vitro Diagnostics (IVD) and Targeted Therapies: The Core of Personalised Medicine
2.3.1 What are In Vitro Diagnostic (IVD) Tests?
2.3.2 How IVDs Help Provide Personalised Treatment
2.4 Companion Diagnostics: Tools for Personalised Medicine
2.4.1 Theranostics: A Subset of Companion Diagnostics
2.5 Biomarkers to Companion Diagnostics
2.5.1 Genomic Biomarkers
2.5.2 Genomic Biomarkers in Oncology
2.6 Development of Companion Diagnostics

3. The World Companion Diagnostics Market, 2010-2021
3.1 Scope and Limitations
3.2 Total Companion Diagnostics Market was Worth $1.30bn in 2010
3.3 Sales Forecast for Total Companion Diagnostics Market, 2010-2015
3.4 Sales Forecast for Total Companion Diagnostics Market, 2016-2021
3.5 Companion Diagnostics is One of the Fastest Growing Segments in the IVD Market
3.5.1 Companion Diagnostics Gaining Greater Share of the IVD Market
3.6 Theranostics Constituted 31.5% of the Companion Diagnostics Market in 2010
3.7 Strong Growth in the Theranostics Market, 2011-2021
3.7.1 Theranostics Gaining Greater Share of the Companion Diagnostics Market, 2011-2021

4. Leading National Markets for Companion Diagnostics, 2010-2021
4.1 Leading National Markets for Companion Diagnostics, 2010
4.2 Leading National Markets for Companion Diagnostics: Sales Forecast, 2011-2021
4.2.1 The US Companion Diagnostics Market, 2011-2021
4.2.2 The Leading European Companion Diagnostics Markets, 2011-2021
4.2.3 The Japanese Companion Diagnostics Market, 2011-2021
4.2.4 Emerging-Economy Companion Diagnostics Markets
4.2.4.1 The Chinese Companion Diagnostics Market, 2011-2021
4.2.4.2 The Indian Companion Diagnostics Market, 2011-2021

5. Products in the Companion Diagnostics Market: Marketed and Pipeline, 2011
5.1 Biomarkers Being Developed into Companion Diagnostics
5.2 Market for Companion Diagnostics: Small, but Growing
5.3 A Complex Market with Multiple Regulatory Pathways
5.4 Marketed Theranostics, 2011
5.5 Pipeline Companion Diagnostics
5.6 Oncology is the Leading Indication for the Development of Companion Diagnostics

6. Companion Diagnostics Market Landscape: Companies and Partnerships, 2010-2011
6.1 Overview
6.2 Stakeholders in the Companion Diagnostics Market
6.2.1 Regulatory Authorities Promoting the Development of Companion Diagnostics
6.2.2 Testing Laboratories
6.2.3 Physicians and Patients: Need to be More Informed to Drive Treatment Decisions
6.2.4 The Market for Theranostic Products is Creating Opportunities for Pharmaceutical and Diagnostic Companies
6.3 Benefits of Employing Companion Diagnostics: Perspective of Pharmaceutical and Diagnostic Companies
6.4 Companies in the Companion Diagnostics Market
6.4.1 Factors Driving Companies to Enter the Companion Diagnostics Market
6.4.2 Companies in the Companion Diagnostics Market: Developing Products and Providing Services
6.5 Business Models for the Development of Companion Diagnostics
6.5.1 Few Pharmaceutical Companies Have Dedicated Diagnostics Units
6.5.2 Collaborating with Pharmaceuticals: A Win-Win for Diagnostic Companies
6.5.3 Roche: A One Stop Shop for Companion Diagnostics
6.5.4 Qiagen: Growing on the Partnership Model
6.6 Deals for Development of Companion Diagnostics, 2010-2011

7. SWOT Analysis of the Companion Diagnostics Market
7.1 Introduction
7.2 Strengths and Weaknesses of the Sector
7.2.1 Maximising Benefits to Healthcare Stakeholders
7.2.2 Minimising Harm
7.2.3 Increasing Compliance
7.2.4 Streamlining Clinical Trials
7.2.5 Reviving Failed or Withdrawn Drugs
7.2.6 Reducing the Costs of Healthcare
7.2.7 Shifting From Reaction to Prevention
7.2.8 The Field of Diagnostics Has Traditionally Been an Undervalued Area of Science When Compared to the Production of Pharmaceuticals
7.2.9 Perceived Lower Revenues and Higher Marketing Costs
7.3 Opportunities and Threats
7.3.1 Biomarkers: Translating into Companion Diagnostics
7.3.2 Reimbursement Challenges
7.3.3 Lack of Clear Regulatory Guidelines on Companion Diagnostics
7.3.4 Complex Business Models: Contradicting Objectives
7.3.5 Threat to the Blockbuster Model of Pharmaceutical Companies

8. Expert Opinion
8.1 Director from a Diagnostics Company in the Sector (Views Provided Anonymously)
8.1.1 Most-Promising Therapeutic Areas for IVD
8.1.2 Unmet Medical Needs in IVD
8.1.3 Greatest Obstacles to Market Growth
8.1.4 Prospects for IVD Market Growth in Developing Countries
8.1.5 Prospects for Theranostics
8.2 Interview with Herbie Newell, Professor of Cancer Therapeutics, Northern Institute for Cancer Research, University of Newcastle, UK
8.2.1 The Importance of Biomarkers for Cancer Therapy
8.2.2 Technological Platforms Used in the Discovery of Novel Biomarkers
8.2.3 The Challenges of Translating Cancer Biomarker Discoveries to the Clinic
8.2.4 Cancer Heterogeneity and Targeted Therapy
8.2.5 Reform in Pharmaceutical R&D and the Importance of Public-Private Partnerships
8.2.6 Current Trends and the Future of Cancer Research
8.3 Vice President, Diagnostics Division of a Global Pharmaceutical Company (Views Provided Anonymously)
8.3.1 Definition of Companion Diagnostics
8.3.2 Pharmaceutical Company and Companion Diagnostics Market
8.3.3 Drivers and Restraints for Companion Diagnostics Market
8.3.4 Most Promising Therapeutic Areas for Development of Companion Diagnostic Tests
8.3.5 Recent Trends in the Companion Diagnostics Market and Future Growth

9. Conclusions
9.1 Overview
9.2 Prominent Companies in the Market
9.3 Commercial Drivers of the Companion Diagnostics Market
9.4 Pharmacogenomics: Driving the Personalised Medicine Approach
9.5 Personalised Medicine is a Strong Driver of the Theranostics Sector
9.6 Commercial Restraints in the Companion Diagnostics Market
9.7 Targeted Therapies Will Revolutionise the Current Model of Pharmaceutical R&D
9.8 Future Outlook and Concluding Remarks

Appendix A
Appendix B
Visiongain report evaluation form

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Telecoms, Energy, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

For an exec summary please email Sara Peerun

Email: sara.peerun@visiongainglobal.com

Tel: +44(0)207-336-6100

Web: www.visiongainglobal.com

.